Lenvatinib plus letrozole versus fulvestrant for metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 study compares a combination medicine (lenvatinib plus letrozole) against fulvestrant to treat metastatic estrogen-receptor positive, HER2-negative breast cancer after the cancer has grown despite hormone therapy plus a CDK4/6 inhibitor. It may help by finding a more effective treatment option after your first lines have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and age 18 or older.
- Your breast cancer must be ER-positive (at least 1% by lab testing) and HER2-negative.
- Your cancer must have grown after first-line hormone (endocrine) treatment plus a CDK4/6 inhibitor; you may have had letrozole before.
- In metastatic disease, you should have had only one prior hormone (endocrine) therapy line, and no more than one prior chemotherapy line.
- You must have measurable tumors on scans, be well enough to do daily activities (ECOG 0–1), and expect to live at least 12 weeks.
- You must have test results that show good blood counts, liver and kidney function, and normal thyroid tests (or thyroid that can be controlled with treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
This trial tests a new medicine called fulvestaciclib combined with hormone therapy and anti-HER2 treatment for advanced breast cancer that is hormone receptor-positive and HER2-positive. It is for patients who have not had prior treatment for advanced disease and may help control tumor growth.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This trial tests a new drug called tinengotinib combined with the hormone therapy fulvestrant for people with HR-positive, HER2-negative breast cancer that has come back or spread. It is for those who have already tried a CDK4/6 inhibitor and at least one hormone therapy.
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.